Talazoparib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Talazoparib
Accession Number
DB11760
Type
Small Molecule
Groups
Investigational
Description

Talazoparib is under investigation for the treatment of Childhood Solid Tumors.

Structure
Thumb
Synonyms
Not Available
External IDs
BMN 673 / BMN-673 / LT-673
Categories
UNII
9QHX048FRV
CAS number
1207456-01-6
Weight
Average: 380.359
Monoisotopic: 380.119715421
Chemical Formula
C19H14F2N6O
InChI Key
HWGQMRYQVZSGDQ-HZPDHXFCSA-N
InChI
InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1
IUPAC Name
(11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(1-methyl-1H-1,2,4-triazol-5-yl)-2,3,10-triazatricyclo[7.3.1.0^{5,13}]trideca-1,5,7,9(13)-tetraen-4-one
SMILES
CN1N=CN=C1[[email protected]@H]1[[email protected]](NC2=C3C1=NNC(=O)C3=CC(F)=C2)C1=CC=C(F)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Talazoparib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Talazoparib.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Talazoparib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Talazoparib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Talazoparib.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Talazoparib.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Talazoparib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Talazoparib.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Talazoparib.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Talazoparib.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Talazoparib.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Talazoparib.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Talazoparib.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Talazoparib.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Talazoparib.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Talazoparib.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Talazoparib.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Talazoparib.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Talazoparib.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
44819241
PubChem Substance
347828114
ChemSpider
28637772
ChEMBL
CHEMBL3137320
HET
2YQ
PDB Entries
4pjt / 4pjv / 4und

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
1Active Not RecruitingTreatmentBRCA-mutated Solid Tumor / Triple Negative Metastatic Breast Cancer1
1Active Not RecruitingTreatmentMetastatic Cancers / Unspecified Adult Solid Tumor1
1CompletedOtherHuman Volunteers1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced or Recurrent Solid Tumors / Ewing's Sarcoma (ES) / Malignant Neoplasm of Pancreas / Neoplasms, Breast / Ovarian Cancer, Epithelial / Prostate Cancer / Small Cell Lung Carcinoma1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia Acute Myeloid Leukemia (AML) / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome1
1Not Yet RecruitingTreatmentEstrogen Receptor Negative / Head and Neck Squamous Cell Carcinoma (HNSCC) / HER2/Neu Negative / Hormone-Resistant Prostate Cancer / Pancreatic Adenocarcinoma Metastatic / Progesterone Receptor Negative / Solid Neoplasms / Stage III Mesothelioma / Stage IIIA Gastric Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Small Cell Lung Carcinoma / Stage IIIB Gastric Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Small Cell Lung Carcinoma / Stage IIIC Gastric Cancer / Stage IIIC Ovarian Cancer / Stage IV Mesothelioma / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Cancer / Stage IV Small Cell Lung Carcinoma / Triple-Negative Breast Carcinoma1
1RecruitingTreatmentAdvanced Malignant Solid Neoplasm / BRCA Rearrangement / BRCA1 Gene Mutation / Brca2 Gene Mutation / Deleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Metastatic Malignant Solid Neoplasm / Solid Neoplasms / Unresectable Solid Neoplasm1
1RecruitingTreatmentAdvanced Solid Tumors3
1RecruitingTreatmentChildhood Solid Tumors1
1RecruitingTreatmentTumors, Solid1
1WithdrawnTreatmentAdult Solid Neoplasm / Estrogen Receptor Negative / Fallopian Tube Serous Neoplasm / HER2/Neu Negative / Ovarian Serous Adenocarcinoma / Ovarian Serous Tumor / Primary Peritoneal Serous Adenocarcinoma / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Triple-Negative Breast Carcinoma1
1WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Carcinoma (NSCLC) / Tumors, Solid1
1, 2CompletedTreatmentAdvanced Breast Cancer / Advanced Ovarian Cancer / Advanced Solid Tumors / Primary Peritoneal Cancer1
1, 2Not Yet RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentAdult Solid Neoplasm / Childhood Solid Neoplasm / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Central Nervous System Neoplasm / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Malignant Solid Neoplasm / Refractory Central Nervous System Neoplasm1
2Active Not RecruitingTreatmentAdvanced Cancers1
2Active Not RecruitingTreatmentBRCA 1 Gene Mutation / BRCA 2 Gene Mutation / Neoplasms, Breast1
2CompletedTreatmentCancer, Ovarian1
2RecruitingTreatmentAdvanced Breast Cancer / HER2/Neu Negative / Triple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentCancers1
2RecruitingTreatmentProstate Cancer1
2WithdrawnTreatmentCancer, Ovarian1
2WithdrawnTreatmentEndometrial Cancers1
3Active Not RecruitingTreatmentBRCA 1 Gene Mutation / BRCA 2 Gene Mutation / Neoplasms, Breast1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.101 mg/mLALOGPS
logP2.93ALOGPS
logP2.11ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)9.48ChemAxon
pKa (Strongest Basic)1.66ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area84.2 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity111.27 m3·mol-1ChemAxon
Polarizability35.82 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Phenylquinolines
Direct Parent
Phenylquinolines
Alternative Parents
Phthalazinones / Secondary alkylarylamines / Pyridazinones / Fluorobenzenes / Aralkylamines / Aryl fluorides / Triazoles / Heteroaromatic compounds / Lactams / Azacyclic compounds
show 4 more
Substituents
Phenylquinoline / Phthalazinone / Phthalazine / Fluorobenzene / Halobenzene / Pyridazinone / Secondary aliphatic/aromatic amine / Aralkylamine / Aryl halide / Aryl fluoride
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:45 / Updated on November 09, 2017 04:56